The chances of US pharma major Eli Lilly (NYSE: LLY) hanging onto market exclusivity with its chemotherapy drug Alimta (pemetrexed for injection) until 2022 were given a fresh boost on Thursday.
With sales of $2.3 billion last year, Alimta is Lilly’s best-selling oncology product. Its indications are for the treatment of pleural mesothelioma and non-small cell lung cancer.
"We continue to emphasize that protection of IP rights is extremely important to the biopharmaceutical industry and the patients we serve"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze